These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 16827622

  • 1. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF.
    J Immunother; 2010 Jun; 33(2):178-84. PubMed ID: 20145546
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 12. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R.
    N Engl J Med; 1992 Oct 22; 327(17):1209-15. PubMed ID: 1406793
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 22; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R, Levy R.
    Blood Rev; 2009 May 22; 23(3):137-42. PubMed ID: 18951668
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS.
    Expert Opin Biol Ther; 2007 Jan 22; 7(1):113-22. PubMed ID: 17150023
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.